GLAXOSMITHKLINE PHARMACEUTICALS
|
GLAXOSMITHKLINE PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 61.15 | 54.76 | 34.83 | 36.05 | 100.04 |
| CEPS(Rs) | 65.08 | 58.70 | 38.94 | 39.75 | 26.50 |
| DPS(Rs) | 57.00 | 54.00 | 32.00 | 32.00 | 90.00 |
| Book NAV/Share(Rs) | 134.77 | 116.06 | 105.47 | 102.89 | 157.19 |
| Tax Rate(%) | 26.32 | 26.38 | 27.72 | 27.35 | 51.12 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 31.01 | 28.56 | 24.01 | 22.54 | 21.20 |
| EBIT Margin(%) | 33.36 | 30.59 | 21.61 | 23.49 | 21.73 |
| Pre Tax Margin(%) | 33.30 | 30.56 | 21.57 | 23.44 | 21.67 |
| PAT Margin (%) | 24.54 | 22.50 | 15.59 | 17.03 | 10.59 |
| Cash Profit Margin (%) | 26.11 | 24.12 | 17.43 | 18.87 | 12.49 |
| Performance Ratios | |||||
| ROA(%) | 25.40 | 25.15 | 17.87 | 15.76 | 10.11 |
| ROE(%) | 48.76 | 49.43 | 33.43 | 27.58 | 18.39 |
| ROCE(%) | 66.79 | 67.64 | 46.49 | 38.06 | 37.72 |
| Asset Turnover(x) | 1.04 | 1.12 | 1.15 | 0.93 | 0.95 |
| Sales/Fixed Asset(x) | 6.11 | 6.20 | 5.84 | 5.82 | 6.03 |
| Working Capital/Sales(x) | 2.31 | 2.74 | 2.97 | 3.06 | 1.79 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.16 | 0.16 | 0.17 | 0.17 | 0.17 |
| Receivable days | 24.45 | 22.78 | 19.98 | 20.34 | 21.37 |
| Inventory Days | 40.60 | 44.57 | 47.50 | 50.87 | 54.91 |
| Payable days | 172.70 | 174.99 | 144.03 | 143.05 | 140.69 |
| Valuation Parameters | |||||
| PER(x) | 37.34 | 52.55 | 55.80 | 36.73 | 16.62 |
| PCE(x) | 35.09 | 49.02 | 49.90 | 33.31 | 62.75 |
| Price/Book(x) | 16.94 | 24.79 | 18.42 | 12.87 | 10.58 |
| Yield(%) | 2.50 | 1.88 | 1.65 | 2.42 | 5.41 |
| EV/Net Sales(x) | 9.76 | 12.63 | 9.22 | 6.54 | 7.84 |
| EV/Core EBITDA(x) | 25.64 | 35.77 | 30.89 | 23.51 | 30.67 |
| EV/EBIT(x) | 26.47 | 37.54 | 38.94 | 25.38 | 32.89 |
| EV/CE(x) | 16.45 | 24.26 | 17.92 | 12.22 | 5.68 |
| M Cap / Sales | 10.12 | 13.00 | 9.53 | 6.90 | 8.59 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 1.93 | 8.56 | 6.21 | -0.80 | 12.05 |
| Core EBITDA Growth(%) | 9.92 | 28.32 | 13.96 | 8.03 | 18.19 |
| EBIT Growth(%) | 11.70 | 54.18 | -2.41 | 7.32 | 70.71 |
| PAT Growth(%) | 11.69 | 57.23 | -2.91 | 59.58 | 32.55 |
| EPS Growth(%) | 11.69 | 57.23 | -3.39 | -63.97 | 373.19 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 2.03 | 1.79 | 1.84 | 1.88 | 2.18 |
| Quick Ratio(x) | 1.77 | 1.54 | 1.49 | 1.53 | 1.87 |
| Interest Cover(x) | 515.59 | 960.03 | 454.77 | 462.54 | 391.29 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of GLAXOSMITHKLINE PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAXOSMITHKLINE PHARMACEUTICALS | ₹45,553.4 Cr | 3.4% | 7.3% | -0.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹461,848.0 Cr | -1.4% | -1.3% | 21.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹225,648.0 Cr | 2.7% | 16.1% | 38.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,109.0 Cr | -1.5% | -3.3% | 35.6% | Stock Analytics | |
| CIPLA | ₹117,139.0 Cr | -0.7% | 1.4% | -2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,328.0 Cr | 3.9% | -1.8% | 0.4% | Stock Analytics | |
GLAXOSMITHKLINE PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAXOSMITHKLINE PHARMACEUTICALS | 3.4% |
7.3% |
-0.5% |
| SENSEX | -0.6% |
1.1% |
-3.2% |
You may also like the below Video Courses
